| Literature DB >> 31121257 |
Alexandre Umpierrez Amaral1, Bianca Seminotti2, Janaína Camacho da Silva2, Francine Hehn de Oliveira3, Rafael Teixeira Ribeiro2, Guilhian Leipnitz4, Diogo Onofre Souza4, Moacir Wajner5.
Abstract
Glutaric acidemia type I (GA I) is a neurometabolic disorder of lysine (Lys) catabolism caused by glutaryl-CoA dehydrogenase (GCDH) deficiency. Patients are susceptible to develop acute striatum degeneration during catabolic stress situations whose underlying mechanisms are not fully established. Thus, in the present work we investigated the effects of a single intrastriatal Lys administration (1.5-4 μmol) to 30-day-old wild type (WT) and GCDH deficient (Gcdh-/-) mice on brain morphology, neuronal injury, astrocyte reactivity and myelin structure, as well as signaling pathways of redox homeostasis. We observed a marked vacuolation/edema in striatum and at higher doses also in cerebral cortex of Gcdh-/-, but not of WT mice. Lys also provoked a reduction of NeuN and synaptophysin, as well as an increase of astrocytic GFAP, in the striatum of Gcdh-/- mice, indicating neuronal loss and astrocyte reactivity. Furthermore, we verified an increase of Nrf2 and NF-κB expression in the nuclear fraction, and a decrease of heme oxygenase-1 (HO-1) content in the striatum of Lys-injected Gcdh-/- mice, implying disruption of redox homeostasis. Finally, it was found that Lys provoked alterations of myelin structure reflected by decreased myelin basic protein (MBP) in the cerebral cortex of Gcdh-/- mice. Taken together, the present data demonstrate neuronal loss, gliosis, altered redox homeostasis and demyelination caused by acute Lys overload in brain of Gcdh-/- mice, supporting the hypothesis that increased brain concentrations of glutaric and 3-hydroxyglutaric acids formed from Lys may be responsible for the acute brain degeneration observed in GA I patients during episodes of metabolic decompensation.Entities:
Keywords: 3-Hydroyglutaric acid; Brain histopathology; Glutaric acid; Glutaric acidemia type I; Glutaryl-CoA dehydrogenase deficiency; Lysine administration
Mesh:
Substances:
Year: 2019 PMID: 31121257 DOI: 10.1016/j.neuint.2019.104467
Source DB: PubMed Journal: Neurochem Int ISSN: 0197-0186 Impact factor: 3.921